These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 687020)

  • 21. Clinical aspects of uraemic polyneuropathy.
    Jennekens FG; Mees EJ; Most van Spijk D van
    Nephron; 1971; 8(5):414-26. PubMed ID: 4332580
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical aspects of uraemic polyneuropathy.
    Jennekens FG; Mees EJ; van de Most van Spijk D
    Nephron; 1971; 8(5):414-26. PubMed ID: 4331711
    [No Abstract]   [Full Text] [Related]  

  • 23. Uremic neurotoxin in the middle molecular weight range.
    Man NK; Cueille G; Zingraff J; Boudet J; Sausse A; Funck-Brentano JL
    Artif Organs; 1980 May; 4(2):116-20. PubMed ID: 7396764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nervous system complications in uremia.
    Fraser CL; Arieff AI
    Ann Intern Med; 1988 Jul; 109(2):143-53. PubMed ID: 2837930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical and metabolic consequences of uremic toxicity].
    Rutkowski P
    Przegl Lek; 2006; 63(4):209-17. PubMed ID: 17080744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.
    Lesaffer G; De Smet R; Lameire N; Dhondt A; Duym P; Vanholder R
    Nephrol Dial Transplant; 2000 Jan; 15(1):50-7. PubMed ID: 10607767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Removal of endogenous middle molecules by hemoperfusion.
    Asaba H; Bergström J; Fürst P; Gunnarsson B; Neuhauser M; Oulès R; Yahiel V
    Artif Organs; 1979 May; 3(2):132-6. PubMed ID: 533396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uremia with low serum creatinine-an entity produced by marked creatinine secretion.
    Bastl C; Katz MA; Shear L
    Am J Med Sci; 1977; 273(3):289-92. PubMed ID: 868918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparative isolation of middle molecular weight fractions from the hemofiltrate of patients with chronic uremia.
    Brunner H; Mann H; Essers U; Schultheis R; Byrne T; Heintz R
    Artif Organs; 1978 Nov; 2(4):375-7. PubMed ID: 743009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hydrophobic uremic middle molecules in hemofiltrate of a dialysis patient].
    Konobu K; Matsumoto T; Sawanishi K
    Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):151-60. PubMed ID: 3386019
    [No Abstract]   [Full Text] [Related]  

  • 31. Gel-filtration on psoriasic and uremic serum and dialysis fluid.
    Lamperi S; Buoncristiani U; Carozzi S; Cozzari M; Icardi A; Trasforini D
    Artif Organs; 1981; 4 Suppl():156-9. PubMed ID: 7295083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paired filtration-dialysis (PFD): a separate convective-diffusive system for extracorporeal blood purification in uraemic patients.
    Ghezzi PM; Zucchelli P; Ringoir S; Nigrelli S; Santoro A; Gervasio R; Sanz Moreno C; Vanholder R; Botella J
    Adv Exp Med Biol; 1987; 223():267-75. PubMed ID: 3328955
    [No Abstract]   [Full Text] [Related]  

  • 33. Heme synthesis in anemia of the uremic state.
    Linkesch W; Stummvoll HK; Wolf A; Müller M
    Isr J Med Sci; 1978 Nov; 14(11):1173-6. PubMed ID: 750546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predialysis BUN and creatinine do not predict adequate dialysis, clinical rehabilitation, or longevity.
    Avram MM; Slater PA; Gan A; Iancu M; Pahilan AN; Okanya D; Rajpal K; Paik SK; Zouabi M; Fein PA
    Kidney Int Suppl; 1985 Dec; 17():S100-4. PubMed ID: 3867776
    [No Abstract]   [Full Text] [Related]  

  • 35. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries.
    Asaba H; Alvestrand A; Bergström J; Fürst P; Yahiel V
    Clin Nephrol; 1982 Feb; 17(2):90-5. PubMed ID: 7067171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid improvement of uremic neuropathy on short high-efficiency hemodialysis with special reference to middle molecules.
    Manohar NL; Gorfien PC; Namba T; Louis BM; Lipner HI
    ASAIO Trans; 1987; 33(3):274-9. PubMed ID: 3675953
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of uremic toxins in exacerbating anemia in renal failure.
    Macdougall IC
    Kidney Int Suppl; 2001 Feb; 78():S67-72. PubMed ID: 11168986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do middle molecules cause uremic intoxication? (Con).
    Kjellstrand CM
    Am J Kidney Dis; 1981 Jul; 1(1):51-6. PubMed ID: 7332001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of alterations of uremic retention products upon platelet and peripheral nerve function.
    Lindsay RM; Bolton CF; Clark WF; Linton AL
    Clin Nephrol; 1983 Mar; 19(3):110-5. PubMed ID: 6839559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity of uremia: physiopathology and clinical signs.
    Bergström J
    Contrib Nephrol; 1989; 71():1-9. PubMed ID: 2680257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.